Christine Arndt

Apr 18, 2024 | nature.com | Vilma Dembitz |Jozef Durko |Thomas P. Corner |Christine Arndt |Matthew Bowen |Amelie V. Guitart | +3 more

AbstractAcute myeloid leukemia (AML) is a largely incurable disease, for which new treatments are urgently needed. While leukemogenesis occurs in the hypoxic bone marrow, the therapeutic tractability of the hypoxia-inducible factor (HIF) system remains undefined. Given that inactivation of HIF-1α/HIF-2α promotes AML, a possible clinical strategy is to target the HIF-prolyl hydroxylases (PHDs), which promote HIF-1α/HIF-2α degradation.